MedTrace Logo

Phase I Study in RAD 001 Patients With Relapse AML

NCT01074086 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2012-12-24

No results posted yet for this study

Summary

A phase I clinical study in evaluation of RAD 001 with aracytine and daunorubicine in AML treatment of patients older less than 65 years in relapse

Conditions

Interventions

DRUG

RAD 001

RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg

Sponsors & Collaborators

Principal Investigators

  • Sophie PARK, MD MS · French Innovative Leukemia Organisation

  • Didier BOUSCArY, MD MS · French Innovative Leukemia Organisation

Study Design

Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01074086 on ClinicalTrials.gov